{"id":"recombinant-gm-csf","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Leukocytosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GM-CSF (granulocyte-macrophage colony-stimulating factor) is a cytokine that promotes the differentiation and proliferation of hematopoietic progenitor cells into granulocytes and macrophages. By increasing the number and activity of these immune cells, it enhances the body's ability to fight infections and potentially tumors. This mechanism makes it useful as an immunostimulatory agent in cancer therapy and infectious disease contexts.","oneSentence":"Recombinant GM-CSF stimulates the production and activation of granulocytes and macrophages to enhance immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:30.361Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer immunotherapy (various malignancies in phase 3 development)"},{"name":"Mobilization of hematopoietic stem cells"}]},"trialDetails":[{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT06431776","phase":"PHASE3","title":"Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).","status":"RECRUITING","sponsor":"Savara Inc.","startDate":"2025-10-22","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":5},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT07341360","phase":"EARLY_PHASE1","title":"Pseudovax - A Cancer Vaccine for Patients With Pseudomyxoma Peritonei","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-10-13","conditions":"Pseudomyxoma Peritonei","enrollment":10},{"nctId":"NCT06546098","phase":"","title":"Molgramostim Nebulizer Solution Expanded Access Program Protocol","status":"AVAILABLE","sponsor":"Savara Inc.","startDate":"","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":""},{"nctId":"NCT03790670","phase":"PHASE1","title":"Biomarker Assessments of Leukine During Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2019-01-30","conditions":"Parkinson Disease","enrollment":7},{"nctId":"NCT06626516","phase":"PHASE1, PHASE2","title":"Tebentafusp-tebn With LDT in Metastatic UM","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-15","conditions":"Metastatic Uveal Melanoma","enrollment":109},{"nctId":"NCT04725331","phase":"PHASE1, PHASE2","title":"A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors","status":"TERMINATED","sponsor":"Transgene","startDate":"2021-02-25","conditions":"Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma","enrollment":31},{"nctId":"NCT05677633","phase":"PHASE1","title":"Biomarker Validation Following Sargramostim Treatment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2023-01-19","conditions":"Parkinson's Disease and Parkinsonism","enrollment":11},{"nctId":"NCT00669734","phase":"PHASE1","title":"Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-02-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma","enrollment":18},{"nctId":"NCT04544293","phase":"PHASE3","title":"Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Savara Inc.","startDate":"2021-05-19","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":164},{"nctId":"NCT04386967","phase":"PHASE1, PHASE2","title":"OH2 Injection in Solid Tumors","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2018-11-22","conditions":"Solid Tumor, Melanoma","enrollment":30},{"nctId":"NCT04616443","phase":"PHASE1, PHASE2","title":"OH2 Injection in Combination With HX008 for Melanoma.","status":"RECRUITING","sponsor":"Binhui Biopharmaceutical Co., Ltd.","startDate":"2020-12-01","conditions":"Melanoma","enrollment":60},{"nctId":"NCT07027748","phase":"PHASE1","title":"Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma","status":"RECRUITING","sponsor":"Steven DuBois, MD","startDate":"2025-06-27","conditions":"Neuroblastoma, Neuroblastoma Recurrent, Relapsed Neuroblastoma","enrollment":18},{"nctId":"NCT06013618","phase":"PHASE2","title":"Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen University Cancer Center","startDate":"2023-06-19","conditions":"Neuroblastoma","enrollment":120},{"nctId":"NCT06989333","phase":"PHASE2","title":"Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis","status":"NOT_YET_RECRUITING","sponsor":"Jiuwu Bai","startDate":"2025-07-01","conditions":"Pulmonary Alveolar Proteinosis","enrollment":10},{"nctId":"NCT04418219","phase":"PHASE1, PHASE2","title":"Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Thomas Jefferson University","startDate":"2020-12-21","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":""},{"nctId":"NCT05482334","phase":"PHASE2","title":"Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2023-10-23","conditions":"Down Syndrome","enrollment":""},{"nctId":"NCT03686683","phase":"PHASE3","title":"Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2018-10-18","conditions":"Adenocarcinoma of the Prostate","enrollment":532},{"nctId":"NCT00901511","phase":"PHASE2","title":"Inhaled GM-CSF Therapy of Autoimmune PAP","status":"COMPLETED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2009-07","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":18},{"nctId":"NCT03421743","phase":"PHASE2","title":"Pilot Trial of Inhaled Molgramostim in Non-tuberculous Mycobacterial (NTM) Infection","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2018-03-01","conditions":"Mycobacterium Infections, Nontuberculous","enrollment":32},{"nctId":"NCT03482752","phase":"PHASE3","title":"Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis","status":"TERMINATED","sponsor":"Savara Inc.","startDate":"2018-04-16","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":60},{"nctId":"NCT04408092","phase":"EARLY_PHASE1","title":"Study of the Effect of GM-CSF on Macrophages in Ependymoma","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-06-25","conditions":"Ependymoma, Recurrent Childhood, Ependymoma","enrollment":6},{"nctId":"NCT06047860","phase":"PHASE2","title":"A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-06-16","conditions":"Advanced Solid Tumor, Refractory Tumor","enrollment":30},{"nctId":"NCT01511068","phase":"PHASE2","title":"Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2012-08","conditions":"Hereditary Pulmonary Alveolar Proteinosis","enrollment":2},{"nctId":"NCT04411680","phase":"PHASE2","title":"Study of Sargramostim in Patients With COVID-19","status":"COMPLETED","sponsor":"Partner Therapeutics, Inc.","startDate":"2020-08-18","conditions":"COVID-19, SARS-CoV-2","enrollment":123},{"nctId":"NCT00046930","phase":"PHASE3","title":"Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2002-09-17","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":449},{"nctId":"NCT03113851","phase":"PHASE2","title":"Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2017-08-14","conditions":"Lung Cancer Metastatic","enrollment":40},{"nctId":"NCT04583969","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":527},{"nctId":"NCT02620865","phase":"PHASE1, PHASE2","title":"BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2015-12","conditions":"Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer","enrollment":2},{"nctId":"NCT05790447","phase":"PHASE2","title":"Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"Advanced Solid Tumor, Refractory Tumor","enrollment":60},{"nctId":"NCT04707664","phase":"PHASE2","title":"Sargramostim Use in COVID-19 to Recover Patient Health","status":"COMPLETED","sponsor":"Partner Therapeutics, Inc.","startDate":"2021-04-27","conditions":"Covid19, SARS-CoV Infection","enrollment":600},{"nctId":"NCT03597347","phase":"PHASE2","title":"Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection","status":"TERMINATED","sponsor":"Savara Inc.","startDate":"2019-06-20","conditions":"Mycobacterium Infections, Nontuberculous, Cystic Fibrosis (CF)","enrollment":14},{"nctId":"NCT03294083","phase":"PHASE1, PHASE2","title":"A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2018-06-07","conditions":"Renal Cell Carcinoma","enrollment":89},{"nctId":"NCT05366283","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Sargramostim Administered Subcutaneously, Intravenously, or by Inhalation","status":"COMPLETED","sponsor":"Partner Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Drug Kinetics, Drug Effects on Physiology","enrollment":42},{"nctId":"NCT02977156","phase":"PHASE1","title":"Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.","status":"COMPLETED","sponsor":"Centre Leon Berard","startDate":"2017-01-03","conditions":"Metastatic Tumor, Advanced Tumor","enrollment":22},{"nctId":"NCT05451420","phase":"NA","title":"Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy","status":"COMPLETED","sponsor":"Henan Provincial People's Hospital","startDate":"2017-12-01","conditions":"Chronic Hepatitis B","enrollment":33},{"nctId":"NCT05366062","phase":"PHASE2","title":"ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab","status":"NOT_YET_RECRUITING","sponsor":"Epitopoietic Research Corporation","startDate":"2022-07-01","conditions":"Glioma, Malignant","enrollment":28},{"nctId":"NCT04849260","phase":"PHASE1, PHASE2","title":"Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2021-08-26","conditions":"Local Progression or Metastatic Melanoma With Failed First-line Treatment","enrollment":54},{"nctId":"NCT00000681","phase":"PHASE1","title":"A Phase I Study of the Combination of Recombinant GM-CSF, AZT, and Chemotherapy (ABV) (Adriamycin, Bleomycin, Vincristine) in AIDS and Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":24},{"nctId":"NCT00000694","phase":"PHASE1","title":"A Phase I Trial of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (rHuGM-CSF), Recombinant Alpha Interferon and Azidothymidine (AZT) in AIDS-Associated Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"Sarcoma, Kaposi, HIV Infections","enrollment":18},{"nctId":"NCT00001090","phase":"PHASE1","title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":36},{"nctId":"NCT01041638","phase":"PHASE3","title":"Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-12-21","conditions":"High Risk Neuroblastoma","enrollment":105},{"nctId":"NCT03006146","phase":"PHASE1","title":"Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2017-07-13","conditions":"Autoimmune Pulmonary Alveolar Proteinosis","enrollment":10},{"nctId":"NCT01438112","phase":"PHASE2, PHASE3","title":"Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"CG Oncology, Inc.","startDate":"2014-03","conditions":"Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ","enrollment":22},{"nctId":"NCT04197882","phase":"PHASE1","title":"Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-05-27","conditions":"Melanoma","enrollment":33},{"nctId":"NCT02411786","phase":"PHASE1","title":"A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2015-08-24","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT01636284","phase":"PHASE2","title":"A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2012-06","conditions":"Hepatocellular Carinoma","enrollment":16},{"nctId":"NCT01394939","phase":"PHASE1, PHASE2","title":"Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2012-01","conditions":"Colorectal Carcinoma, CRC","enrollment":52},{"nctId":"NCT02562755","phase":"PHASE3","title":"Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone","status":"COMPLETED","sponsor":"SillaJen, Inc.","startDate":"2015-10","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":459},{"nctId":"NCT00002950","phase":"PHASE1, PHASE2","title":"Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"1996-09-26","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":25},{"nctId":"NCT04200040","phase":"PHASE2","title":"A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients","status":"UNKNOWN","sponsor":"OrienGene Biotechnology Ltd.","startDate":"2017-08-27","conditions":"Melanoma (Skin)","enrollment":165},{"nctId":"NCT03123666","phase":"NA","title":"Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2017-04-19","conditions":"Cirrhosis","enrollment":160},{"nctId":"NCT04206358","phase":"PHASE1","title":"Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2019-05-13","conditions":"Melanoma","enrollment":30},{"nctId":"NCT03794180","phase":"PHASE1","title":"Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects","status":"COMPLETED","sponsor":"I-Mab Biopharma US Limited","startDate":"2019-03-18","conditions":"Healthy Adult Subjects","enrollment":32},{"nctId":"NCT00003727","phase":"PHASE2","title":"Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"1999-03","conditions":"Leukemia","enrollment":22},{"nctId":"NCT03119025","phase":"PHASE1, PHASE2","title":"Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection","status":"COMPLETED","sponsor":"Russian Academy of Medical Sciences","startDate":"2015-05","conditions":"Hepatitis C, Chronic, Liver Diseases, Hepatitis","enrollment":10},{"nctId":"NCT00002787","phase":"PHASE1","title":"Vaccine Therapy in Treating Patients With Multiple Myeloma Who Have Undergone Stem Cell Transplantation","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium","startDate":"1996-03","conditions":"Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma","enrollment":22},{"nctId":"NCT01487863","phase":"PHASE2","title":"Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2011-12","conditions":"Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":69},{"nctId":"NCT02173093","phase":"PHASE1, PHASE2","title":"Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2014-11","conditions":"Disseminated Neuroblastoma, Recurrent Neuroblastoma","enrollment":40},{"nctId":"NCT00450463","phase":"PHASE2","title":"Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-02-23","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT00621036","phase":"PHASE2","title":"Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-10-19","conditions":"Brain and Central Nervous System Tumors, Lymphoma, Lymphoproliferative Disorder","enrollment":""},{"nctId":"NCT01981122","phase":"PHASE2","title":"A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2013-09","conditions":"Metastatic Prostate Cancer","enrollment":52},{"nctId":"NCT03282188","phase":"PHASE1, PHASE2","title":"REO13 Melanoma With of Without GM-CSF","status":"WITHDRAWN","sponsor":"University of Leeds","startDate":"2017-10","conditions":"Melanoma, Cancer of Skin","enrollment":""},{"nctId":"NCT00256282","phase":"PHASE2","title":"Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma","status":"COMPLETED","sponsor":"John P. Fruehauf","startDate":"2003-04","conditions":"Metastatic Melanoma","enrollment":52},{"nctId":"NCT00952237","phase":"PHASE1","title":"Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2003-01","conditions":"Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma","enrollment":13},{"nctId":"NCT03489616","phase":"NA","title":"Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2018-01-15","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00095862","phase":"PHASE1, PHASE2","title":"Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers","status":"TERMINATED","sponsor":"Wiseman Research Initiatives LLC","startDate":"2004-11","conditions":"Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":24},{"nctId":"NCT00779402","phase":"PHASE3","title":"PROvenge Treatment and Early Cancer Treatment","status":"COMPLETED","sponsor":"Dendreon","startDate":"2001-10","conditions":"Prostate Cancer","enrollment":176},{"nctId":"NCT00005987","phase":"PHASE2","title":"Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-08","conditions":"Multiple Myeloma and Plasma Cell Neoplasm","enrollment":87},{"nctId":"NCT00060528","phase":"PHASE1, PHASE2","title":"Sequential Vaccinations in Prostate Cancer Patients","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-05-22","conditions":"Prostatic Neoplasms","enrollment":32},{"nctId":"NCT03048253","phase":"","title":"A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c","status":"UNKNOWN","sponsor":"OrienGene Biotechnology Ltd.","startDate":"2016-03-29","conditions":"Melanoma","enrollment":30},{"nctId":"NCT00228813","phase":"NA","title":"G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome","status":"TERMINATED","sponsor":"Emory University","startDate":"2004-04","conditions":"Hematologic Malignancies","enrollment":8},{"nctId":"NCT00003199","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"1997-11","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer","enrollment":50},{"nctId":"NCT00081848","phase":"PHASE1","title":"Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-04-20","conditions":"Liver Neoplasms","enrollment":12},{"nctId":"NCT00096551","phase":"PHASE1","title":"A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-01","conditions":"Prostatic Neoplasms","enrollment":21},{"nctId":"NCT01338012","phase":"PHASE2","title":"Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Dendreon","startDate":"2011-12","conditions":"Prostate Cancer","enrollment":8},{"nctId":"NCT01431391","phase":"PHASE2","title":"Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2011-09","conditions":"Prostatic Neoplasm, Prostate Cancer, Prostatic Adenocarcinoma","enrollment":68},{"nctId":"NCT00901342","phase":"PHASE2","title":"Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Dendreon","startDate":"2009-10","conditions":"Prostate Cancer","enrollment":104},{"nctId":"NCT00715078","phase":"PHASE2","title":"To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen","status":"COMPLETED","sponsor":"Dendreon","startDate":"2008-10","conditions":"Prostate Cancer","enrollment":122},{"nctId":"NCT00659789","phase":"PHASE2","title":"Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV","status":"COMPLETED","sponsor":"Bionor Immuno AS","startDate":"2008-08","conditions":"HIV I Infection","enrollment":137},{"nctId":"NCT00450619","phase":"PHASE2","title":"153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-02","conditions":"Prostate Cancer","enrollment":44},{"nctId":"NCT02496273","phase":"PHASE1","title":"Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2016-01","conditions":"Gastric Cancer","enrollment":60},{"nctId":"NCT02470559","phase":"PHASE1","title":"Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent","status":"WITHDRAWN","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2015-06","conditions":"Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma","enrollment":""},{"nctId":"NCT00554372","phase":"PHASE2","title":"A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-08","conditions":"Carcinoma, Hepatocellular","enrollment":30},{"nctId":"NCT01169584","phase":"PHASE1","title":"Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2010-08","conditions":"Neuroblastoma, Rhabdomyosarcoma, Lymphoma","enrollment":6},{"nctId":"NCT01171651","phase":"PHASE2","title":"A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2009-08","conditions":"Carcinoma, Hepatocellular","enrollment":25},{"nctId":"NCT01380600","phase":"PHASE1","title":"Safety Study of Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2010-07","conditions":"Carcinoma, Colorectal","enrollment":15},{"nctId":"NCT00201409","phase":"PHASE2","title":"A Randomized Trial of GM-CSF in Patients With ALI/ARDS","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2004-07","conditions":"Respiratory Distress Syndrome, Adult","enrollment":132},{"nctId":"NCT00625456","phase":"PHASE1","title":"Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-06","conditions":"Melanoma, Lung Cancer, Renal Cell Carcinoma","enrollment":23},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT00108732","phase":"PHASE2","title":"A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-02","conditions":"Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":50},{"nctId":"NCT00020254","phase":"PHASE2","title":"Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT00217373","phase":"PHASE1","title":"Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-06","conditions":"Adult Solid Neoplasm","enrollment":33},{"nctId":"NCT01387555","phase":"PHASE2","title":"A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2008-12","conditions":"Hepatocellular Carcinoma, Liver Cancer, HCC","enrollment":129},{"nctId":"NCT00003416","phase":"PHASE2","title":"S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1998-09","conditions":"Lymphoma","enrollment":9},{"nctId":"NCT00429312","phase":"PHASE1, PHASE2","title":"A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma","status":"COMPLETED","sponsor":"Jennerex Biotherapeutics","startDate":"2007-03","conditions":"Melanoma","enrollment":10},{"nctId":"NCT00072137","phase":"PHASE1","title":"Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2003-10","conditions":"Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma","enrollment":21},{"nctId":"NCT00995449","phase":"PHASE2","title":"Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Humanigen, Inc.","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":9},{"nctId":"NCT00006113","phase":"PHASE2","title":"Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma","status":"TERMINATED","sponsor":"University of Southern California","startDate":"1999-06","conditions":"Melanoma (Skin)","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":283,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Recombinant GM-CSF","genericName":"Recombinant GM-CSF","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Recombinant GM-CSF is a small molecule used to treat various conditions, including Neuroblastoma, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma and Plasma Cell Neoplasm, HIV Infections, and Cytopenias. It has been studied in clinical trials in combination with other interventions, such as Naxitamab monotherapy and Irinotecan, for the treatment of these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}